← All trials
NCT06093061
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2023
- Primary completion
- Oct 31, 2028
- Completion date
- Oct 31, 2029
- First posted
- Oct 23, 2023
- Last posted
- Oct 23, 2023
- Enrollment
- 69
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of SingaporeLead sponsor
- BeOne MedicinesCollaborator
- Nanyang Technological UniversityCollaborator
- Government of SingaporeOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.